Acquiring Company
Glaukos Corporation
Acquired Company
Mobius Therapeutics
Aliso ViejoUnited StatesBiotechnologyHealth CareMedicalTherapeuticsPharmaceuticalBiotechnologyHealth CareTherapeuticsDescription
GLAUKOS Corp has acquired Mobius Therapeutics, LLC for $12.4 million, enhancing its product portfolio. The acquisition includes Mitosol, the only FDA-approved ophthalmic formulation of mitomycin-C. This move is expected to significantly improve GLAUKOS's offerings in the ophthalmic market. The deal aligns with GLAUKOS's strategy to expand its range of treatment options.
Who to call at Glaukos Corporation, and when
When Glaukos Corporation changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Glaukos Corporation raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Glaukos Corporation, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Glaukos Corporation makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Mobius Therapeutics?
Mobius Therapeutics was acquired by Glaukos Corporation, based in Aliso Viejo. The deal was reported on February 23, 2026. Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that focuses on developing innovative therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos Corporation is publicly traded (GKOS) and operates in Biotechnology.
When did Glaukos Corporation acquire Mobius Therapeutics?
Glaukos Corporation's acquisition of Mobius Therapeutics was reported on February 23, 2026. GLAUKOS Corp has acquired Mobius Therapeutics, LLC for $12.4 million, enhancing its product portfolio. The acquisition includes Mitosol, the only FDA-approved ophthalmic formulation of mitomycin-C. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Mobius Therapeutics do?
Mobius Therapeutics, LLC specializes in the development of unique ophthalmic products. It is best known for Mitosol, an FDA-approved formulation of mitomycin-C for glaucoma treatment. Mobius aims to improve patient outcomes through innovative therapies. It is privately held, operating in Biotechnology, and is based in United States.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.